![]() While the company reported mixed second-quarter results amid macro pressures, its long-term growth potential looks attractive. Medtech company Intuitive Surgical is a leader in robotic-assisted, minimally invasive surgery, thanks to its da Vinci surgical system. The average price target of $593.31 implies 10.5% upside potential. Wall Street’s Strong Buy consensus rating on Eli Lilly stock is based on 16 Buys and one Hold. He projects LLY’s GLP-1 drug class to deliver revenue of $23 billion and $34 billion in 20, respectively, up from $8 billion in 2022, and then reach $50 billion in 2030. The analyst said that he sees a significant upside to Street estimates, supported by multiple catalysts, including a potential FDA approval of LLY's Alzheimer's therapy donanemab. With Eli Lilly anticipated to be granted FDA approval this year to offer Mounjaro for weight loss, the stock is one of Schott's favorites among GLP-1 developers, with a Buy rating and a price target of $600. ![]() Is Eli Lilly a Good Stock to Buy Now?Įarlier this month, J.P.Morgan analyst Chris Schott raised his projections for weight loss drugs and expects the drug category known as GLP-1 agonists to generate more than $100 billion in annual sales by 2030 in a duopoly controlled by Eli Lilly and Novo Nordisk ( NVO). ![]() The company’s breast cancer pill Verzenio and Type 2 diabetes drug Jardiance also performed well. The second-quarter performance and upgraded guidance were driven by a significant rise in sales of LLY’s diabetes treatment Mounjaro to $979.9 million from $16 million in the prior-year quarter. The company’s Q3 2023 revenue grew 28% to $8.3 billion, while adjusted EPS jumped 69% to $2.11.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |